Journal of pediatric hematology/oncology
-
J. Pediatr. Hematol. Oncol. · Dec 2011
Randomized Controlled Trial Multicenter Study Comparative StudyPolyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Administration of L-asparaginase is limited by hypersensitivity reactions mediated by anti-asparaginase antibodies. To overcome this problem, native Escherichia coli L-asparaginase was conjugated to polyethylene glycol (PEG) to formulate PEG-L-asparaginase, a preparation with decreased immunogenicity and increased circulating half-life. In early trials, PEG-L-asparaginase was tolerated by patients known to be hypersensitive to the native E. coli product. ⋯ PEG asparaginase is a useful agent in patients with allergic reactions to native asparaginase.
-
J. Pediatr. Hematol. Oncol. · Dec 2011
Case ReportsAcute respiratory failure in 3 children with juvenile myelomonocytic leukemia.
Juvenile myelomonocytic leukemia is a rare hematopoietic stem cell disease in children with features of both myelodysplasia and myeloproliferation. Extramedullary involvement has been reported and pulmonary involvement secondary to leukemic infiltration is an initial manifestation, which may result in acute respiratory failure. ⋯ In each case the patients improved rapidly after initiation of antileukemic treatment including 6-mercaptopurine or cytarabine.